Tech Company Financing Transactions
Octant Funding Round
Octant closed a $30 million Series A venture capital round on 5/21/2020. Backers included Andreessen Horowitz, 8VC and Allen & Company.
Transaction Overview
Company Name
Announced On
5/21/2020
Transaction Type
Venture Equity
Amount
$30,000,000
Round
Series A
Investors
Proceeds Purpose
Octant is using the proceeds to further develop its discovery platform, which targets large numbers of G-protein coupled receptors (GPCRs) and their downstream signaling pathways to engineer drugs to treat complex diseases.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
1464 67th St.
Emeryville, CA 94608
USA
Emeryville, CA 94608
USA
Phone
Undisclosed
Website
Email Address
Overview
Octant is advancing a new paradigm of drug discovery. Our polypharmacology discovery engine generates multi-receptor pathway data and predictive insights to inform rational drug design with unprecedented speed, scale and precision. We engineer biology using living cells as high-throughput signal networks to map, measure and model chemical structures against G protein-coupled receptors (GPCRs).
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Sri Kosuri
President
Ramsey Homsany
Browse more venture capital transactions:
Prev: 5/21/2020: FireHydrant venture capital transaction
Next: 5/21/2020: Rapid Micro Biosystems venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on every notable VC transaction. VC investment data records on this site are sourced from company press releases and news coverage. The information is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs